Biostage Stock Price, News & Analysis (OTCMKTS:BSTG)

$0.07 0.00 (0.00 %)
(As of 11/17/2017 05:16 AM ET)
Previous Close$0.07
Today's Range$0.07 - $0.08
52-Week Range$0.05 - $1.42
Volume122,218 shs
Average Volume1.56 million shs
Market Capitalization$2.69 million
P/E RatioN/A
Dividend YieldN/A

About Biostage (OTCMKTS:BSTG)

Biostage logoBiostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:BSTG
  • Previous Symbol: NASDAQ:BSTG
  • CUSIP: N/A
  • Web:
  • Current Ratio: 1.10%
  • Quick Ratio: 1.09%
Sales & Book Value:
  • Annual Sales: $80,000.00
  • Price / Sales: 34.25
  • Book Value: $0.10 per share
  • Price / Book: 0.70
  • Trailing EPS: ($0.61)
  • Net Income: ($11,570,000.00)
  • Return on Equity: -1,031.15%
  • Return on Assets: -229.23%
  • Employees: 28
  • Outstanding Shares: 39,030,000

Frequently Asked Questions for Biostage (OTCMKTS:BSTG)

What is Biostage's stock symbol?

Biostage trades on the OTCMKTS under the ticker symbol "BSTG."

How were Biostage's earnings last quarter?

Biostage, Inc. (OTCMKTS:BSTG) announced its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.09. View Biostage's Earnings History.

Who are some of Biostage's key competitors?

Who are Biostage's key executives?

Biostage's management team includes the folowing people:

  • John F. Kennedy, Chairman of the Board
  • James J. McGorry, Chief Executive Officer, Director
  • Thomas McNaughton Jr., Chief Financial Officer
  • Harout DerSimonian, Chief Scientific Officer
  • David M. Green, Director
  • Blaine H Mckee Ph.D., Director
  • John J. Canepa, Independent Director
  • Thomas H. Robinson, Independent Director

How do I buy Biostage stock?

Shares of Biostage can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biostage's stock price today?

One share of Biostage stock can currently be purchased for approximately $0.07.

How big of a company is Biostage?

Biostage has a market capitalization of $2.69 million and generates $80,000.00 in revenue each year. The biotechnology company earns ($11,570,000.00) in net income (profit) each year or ($0.61) on an earnings per share basis. Biostage employs 28 workers across the globe.

How can I contact Biostage?

Biostage's mailing address is 84 October Hill Rd Ste 11, HOLLISTON, MA 01746-1371, United States. The biotechnology company can be reached via phone at +1-774-2337300 or via email at [email protected]

MarketBeat Community Rating for Biostage (OTCMKTS BSTG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Biostage (OTCMKTS:BSTG)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Biostage (OTCMKTS:BSTG)

Price Target History for Biostage (OTCMKTS:BSTG)

Analysts' Ratings History for Biostage (OTCMKTS:BSTG)

DateFirmActionRatingPrice TargetDetails
8/14/2017Maxim GroupReiterated RatingHoldView Rating Details
(Data available from 11/18/2015 forward)


Earnings History and Estimates Chart for Biostage (OTCMKTS:BSTG)

Earnings by Quarter for Biostage (OTCMKTS:BSTG)

Earnings History by Quarter for Biostage (OTCMKTS BSTG)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.07)($0.10)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.14)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.20)$0.03 millionViewListenView Earnings Details
11/10/2016Q316($0.25)($0.18)$26.00 millionViewN/AView Earnings Details
8/11/2016Q216($0.21)($0.17)$48.00 million$0.03 millionViewListenView Earnings Details
5/12/2016Q1($0.23)($0.18)ViewListenView Earnings Details
3/17/2016Q415($0.17)$1.60 million$0.01 millionViewListenView Earnings Details
11/12/2015Q315($0.19)$37.00 millionViewN/AView Earnings Details
8/13/2015Q215($0.44)$23.00 million$73.00 millionViewN/AView Earnings Details
3/19/2015Q4 2014($0.27)($0.36)$0.05 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.33)($0.34)ViewN/AView Earnings Details
8/8/2014Q214($0.27)($0.32)$0.02 millionViewN/AView Earnings Details
5/8/2014Q114($0.33)($0.39)$0.10 million$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biostage (OTCMKTS:BSTG)

No earnings estimates for this company have been tracked by


Dividend History for Biostage (OTCMKTS:BSTG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biostage (OTCMKTS BSTG)

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 7.15%
Insider Trades by Quarter for Biostage (OTCMKTS:BSTG)

Insider Trades by Quarter for Biostage (OTCMKTS BSTG)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017Saverio LafrancescaInsiderBuy100,000$0.37$37,000.00View SEC Filing  
8/23/2017Saverio LafrancescaInsiderBuy150,000$0.32$48,000.00View SEC Filing  
10/12/2016Harout DersimonianInsiderBuy10,000$0.91$9,100.00View SEC Filing  
8/26/2016John F KennedyDirectorBuy16,182$0.93$15,049.26View SEC Filing  
8/25/2016James Joseph McgorryInsiderBuy25,000$0.96$24,000.00View SEC Filing  
6/21/2016James Joseph McgorryCEOBuy20,000$1.07$21,400.00View SEC Filing  
6/13/2016Thomas H RobinsonDirectorBuy32,000$1.17$37,440.00View SEC Filing  
5/25/2016John J CanepaDirectorBuy17,241$1.46$25,171.86View SEC Filing  
5/20/2016James Joseph McgorryCEOBuy10,000$1.56$15,600.00View SEC Filing  
5/20/2016John F KennedyDirectorBuy6,500$1.56$10,140.00View SEC Filing  
5/20/2016Thomas McnaughtonCFOBuy5,000$1.56$7,800.00View SEC Filing  
5/19/2016Thomas H RobinsonDirectorBuy18,000$1.36$24,480.00View SEC Filing  
12/17/2015Saverio LafrancescainsiderSell2,393$1.93$4,618.49View SEC Filing  
12/1/2015John F KennedyDirectorBuy9,000$2.95$26,550.00View SEC Filing  
12/1/2015Saverio LafrancescaInsiderBuy10,000$3.01$30,100.00View SEC Filing  
11/19/2015James Joseph McgorryCEOBuy10,000$1.79$17,900.00View SEC Filing  
11/18/2015Thomas McnaughtonCFOBuy10,000$1.56$15,600.00View SEC Filing  
11/17/2015David GreenDirectorBuy25,000$1.34$33,500.00View SEC Filing  
11/17/2015Thomas McnaughtonCFOBuy15,000$1.32$19,800.00View SEC Filing  
9/18/2015Saverio LafrancescainsiderBuy9,500$1.29$12,255.00View SEC Filing  
8/28/2015Saverio LafrancescaInsiderBuy2,500$0.96$2,400.00View SEC Filing  
8/26/2015Thomas McnaughtonCFOBuy10,000$0.88$8,800.00View SEC Filing  
8/24/2015John F KennedyDirectorBuy12,000$0.83$9,960.00View SEC Filing  
8/21/2015James Joseph McgorryCEOBuy31,300$0.74$23,162.00View SEC Filing  
8/21/2015Thomas McnaughtonCFOBuy100,000$0.66$66,000.00View SEC Filing  
6/4/2015John F KennedyDirectorBuy1,000$2.13$2,130.00View SEC Filing  
6/3/2015John F KennedyDirectorBuy1,000$1.95$1,950.00View SEC Filing  
6/3/2015Thomas McnaughtonCEOBuy16,000$1.85$29,600.00View SEC Filing  
6/2/2015David GreenDirectorBuy26,600$1.81$48,146.00View SEC Filing  
6/2/2015Thomas McnaughtonCEOBuy8,000$1.80$14,400.00View SEC Filing  
6/1/2015John F KennedyDirectorBuy10,000$1.67$16,700.00View SEC Filing  
6/1/2015Thomas McnaughtonCEOBuy3,000$1.74$5,220.00View SEC Filing  
5/29/2015Thomas McnaughtonCEOBuy5,000$1.91$9,550.00View SEC Filing  
2/18/2015David GreenCEOBuy50,000$1.75$87,500.00View SEC Filing  
2/13/2015Thomas McnaughtonCFOBuy14,000$2.67$37,380.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biostage (OTCMKTS:BSTG)

Latest Headlines for Biostage (OTCMKTS BSTG)

No headlines for this company have been tracked by

Social Media



Biostage (OTCMKTS BSTG) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.